
CCassured
CCassured
1 Projects, page 1 of 1
Open Access Mandate for Publications and Research data assignment_turned_in Project2023 - 2026Partners:ICCS, SERVTECH, CCassured, UMC-Mainz, HELLENIC SOCIETY OF GASTROINTESTINAL ONCOLOGY +35 partnersICCS,SERVTECH,CCassured,UMC-Mainz,HELLENIC SOCIETY OF GASTROINTESTINAL ONCOLOGY,VITO,CSIC,UNIVERSITEIT VAN TILBURG,CATALINK,UR,Konnekt-able Technologies,CCassured,UNIVERSITE MARIE ET LOUIS PASTEUR,CERTH,FUNDATIA YOUTH CANCER EUROPE,GIE AXA,INNOVATION SPRINT,TIMELEX,AINIGMA,Ministry of Health,Carr Comm,BEIA,UKSH,UMINHO,PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJA,EUROPAISCHE VEREINIGUNG DER GASTROINTESTINALEN ONKOLOGIE(EUROPEAN SOCIETY OF DIGESTIVE ONCOLOGY - ESDO),Technion – Israel Institute of Technology,MUG,MUI,ERNST & YOUNG FINANCIAL BUSINESS ADVISORS SPA,Firalis (France),UFC,ASSOCIATION GERCOR,LSMU,INSTITUTUL ONCOLOGIC PROF. DR. ALEXANDRU TRESTIOREANU BUCURESTI,ROSENBAUM CONSULTING,IPOPORTO,EUROPACOLON PORTUGAL- ASSOCIACAO DE LUTA CONTRA O CANCRO DO INTESTINO,MINISTRY OF HEALTH OF THE REPUBLIC OF LITHUANIA,EXUS SOFTWARESINGLE MEMBER LIMITED LIABILITY COMPANYFunder: European Commission Project Code: 101097036Overall Budget: 12,972,100 EURFunder Contribution: 12,972,100 EURWith Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease. ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising. Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed. The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.
more_vert